Antipsychotic Drugs

The D1-like family includes the D1 and D5 receptors. These receptors couple to stimulatory G proteins (Gs), which activate adenylyl cyclase and increase cyclic adenosine monophosphate (cyclic AMP) inside the cell. The net effect of D1 family activation is generally excitatory — it increases the activity of the neurons that express these receptors.

D1 receptors are the most abundant dopamine receptors in the brain and are expressed at high density in the prefrontal cortex, striatum, and nucleus accumbens. In the prefrontal cortex, D1 receptor stimulation supports working memory by maintaining the persistent neuronal firing that underlies short-term information storage. The mesocortical dopamine deficiency in schizophrenia reduces D1 stimulation in the prefrontal cortex, which is one reason working memory and executive function are impaired. No currently approved antipsychotic directly targets D1 receptors.

The D2-like family includes the D2, D3, and D4 receptors. These receptors couple to inhibitory G proteins (Gi), which inhibit adenylyl cyclase and decrease cyclic AMP. Their activation generally reduces the activity of the neurons that express them.

The D2 receptor is the primary target of all currently approved antipsychotics. It is expressed at high density in the striatum, nucleus accumbens, pituitary gland, and to a lesser degree in the prefrontal cortex. Every drug capable of producing antipsychotic effect achieves this by occupying D2 receptors — whether it blocks them completely (as first-generation and most second-generation antipsychotics do) or activates them only partially (as partial agonists like aripiprazole do). The D2 receptor is therefore the pharmacological anchor of the entire antipsychotic drug class.

The D3 receptor is concentrated in limbic regions, particularly the nucleus accumbens. Its limbic distribution makes it an attractive target for addressing motivational deficits in negative symptoms with reduced motor side effects, an approach exploited by cariprazine, which preferentially binds D3 over D2. The D4 receptor is found at lower density in the frontal cortex and limbic structures. Clozapine has notably higher D4 affinity relative to D2 compared with other antipsychotics, a property that may contribute to its exceptional efficacy in treatment-resistant schizophrenia, though the exact significance of D4 blockade remains debated.

Positive symptoms are distortions or excesses of normal mental function. The term "positive" refers to the presence of experiences that should not be there — not to anything favorable about them. Positive symptoms include hallucinations (most commonly auditory — hearing voices), delusions (fixed false beliefs, often paranoid in character), disorganized thinking, and bizarre behavior.

Positive symptoms are driven by mesolimbic dopamine excess and are the dimension most responsive to antipsychotic treatment. Most patients with schizophrenia achieve substantial reduction in positive symptoms with adequate antipsychotic therapy. When positive symptoms persist despite two adequate antipsychotic trials at adequate doses — a condition affecting approximately 20 to 30 percent of patients — the patient meets criteria for treatment-resistant schizophrenia, for which clozapine has the strongest evidence base.

Negative symptoms are reductions in or absences of normal mental function. They include blunted affect (reduced emotional expressivity), alogia (reduced verbal output and spontaneity), avolition (reduced motivation and self-directed activity), anhedonia (reduced capacity for pleasure), and asociality (reduced interest in social interaction). These five domains together produce the characteristic withdrawal and motivational poverty seen in chronic schizophrenia.

Negative symptoms arise from mesocortical dopamine deficiency and are the dimension most responsible for long-term functional disability. A patient whose positive symptoms are well controlled but who retains severe avolition and anhedonia may be unable to work, maintain relationships, or live independently. Negative symptoms respond poorly to standard antipsychotic treatment — and first-generation antipsychotics can actually worsen them by further suppressing an already deficient mesocortical dopamine pathway.

An important distinction: negative symptoms can be primary (intrinsic to the illness, reflecting mesocortical dopamine deficiency) or secondary (caused by drug-induced motor side effects that mimic avolition and blunted affect, by depression, or by excessive sedation from medication). Secondary negative symptoms may improve by addressing their underlying cause — reducing extrapyramidal side effects, treating depression, or reducing medication dose.

Cognitive deficits in schizophrenia affect attention, working memory, processing speed, verbal learning, and executive function. They are present before the first psychotic episode, worsen at illness onset, and are strong independent predictors of functional outcome — often more predictive than the severity of positive or negative symptoms.

No currently approved antipsychotic has demonstrated robust improvement in cognitive function beyond what can be explained by reducing positive symptom burden. Anticholinergic medications used to manage drug-induced motor side effects actually worsen cognitive function further, which is one of the reasons minimizing anticholinergic drug exposure in schizophrenia is clinically important.

First-generation antipsychotics produce antipsychotic effect through potent, relatively selective D2 receptor blockade. Because they have limited activity at other receptors, their full D2 blocking activity reaches all four dopaminergic pathways without buffering — which means effective suppression of positive symptoms but a high rate of extrapyramidal symptoms, tardive dyskinesia, and hyperprolactinemia.

Within the first-generation class, agents are categorized by potency — which in this context means the milligram dose required to achieve a therapeutic level of D2 occupancy, not clinical superiority. High-potency agents such as haloperidol and fluphenazine achieve D2 blockade at doses of 2 to 20 milligrams per day and carry the highest risk of extrapyramidal symptoms because of their tight, selective D2 binding. Low-potency agents such as chlorpromazine and thioridazine require doses of 200 to 1000 milligrams per day and carry lower extrapyramidal symptom risk — because their anticholinergic and antihistaminergic activity partially offsets the motor consequences of D2 blockade — but produce more sedation, more anticholinergic effects, and more orthostatic hypotension.

Second-generation antipsychotics combine D2 receptor blockade with additional blockade of serotonin 5-HT2A receptors. This serotonin-dopamine antagonism partially restores dopamine tone in the nigrostriatal and mesocortical pathways, reducing extrapyramidal symptom risk and potentially offering some advantage for negative symptoms. The category is defined not by superior antipsychotic efficacy — they are not more effective than first-generation agents at reducing positive symptoms — but by a lower motor side effect burden at clinically effective doses.

The trade-off for this reduced motor burden is a different adverse effect profile: second-generation antipsychotics as a class produce more weight gain, glucose dysregulation, and dyslipidemia than first-generation agents, effects that are most pronounced with clozapine and olanzapine. Key second-generation agents include clozapine, olanzapine, quetiapine, risperidone, paliperidone, ziprasidone, lurasidone, and asenapine. Their individual profiles are covered in Modules 3 and 4.

A third mechanistic category comprises the partial D2 agonists — aripiprazole, brexpiprazole, and cariprazine. Rather than blocking the D2 receptor completely, these drugs activate it partially. In circuits where dopamine is excessive (mesolimbic pathway in psychosis), the partial agonist competes with dopamine and produces a net reduction in receptor activation — a functional antagonist effect that reduces positive symptoms. In circuits where dopamine is deficient (mesocortical pathway), the partial agonist provides some residual receptor activation that a full antagonist would eliminate entirely.

This mechanism produces a favorable profile: low extrapyramidal symptom risk, minimal prolactin elevation, and — particularly for cariprazine — some benefit for negative symptoms. The characteristic adverse effect of this class is akathisia (a distressing sense of inner restlessness and inability to stay still), which occurs at higher rates with partial agonists than with most second-generation antipsychotics.